Danae UroGenomics S.L.
Contact information
- Biomarkers
- In vitro diagnostics
- Screening
- Oncology
- Kidney and genitourinary system
- Biotechnolgy kits
Danae Urogenomics is a leading company in bladder cancer diagnostics. Our state-of-the-art diagnostic systems allow us to offer high-quality services for the detection and monitoring of this disease. We collaborate with scientific institutions and hospitals to continuously improve our diagnostic and prognostic methods. Our scientific partnerships and institutional collaborations ensure the accuracy and effectiveness of our diagnostics.
Products: BlaDimiR, BlaDimiRplus & BaDimiRIO
It is a non-invasive molecular diagnostic platform based on the detection of a proprietary set of urinary biomarkers, specifically designed for bladder cancer.
It relies on the quantification of three microRNA (miRNA) profile systems and, in its most advanced version, also cytokines, to provide integrated solutions ranging from early diagnosis (BlaDimiR), to prediction of response to BCG immunotherapy (BlaDimiRplus), and to combined BCG and anti-PD-L1 therapies (BlaDimiRIO).
This precision technology enables more informed, personalized, and efficient clinical decision-making without the need for invasive procedures.
Molecular diagnostics companies, companies specialising in regulatory processes, business models, internationalisation.